Proper name: Insulin glargine (rDNA origin) Type: Long-acting insulin diabetes therapeutic Developer: Sanofi-Aventis Location: Paris, France Web address: www.sanofi-aventis.com Indication(s): Adults with Type II diabetes or adults and children (6 years and older) with Type I diabetes who require long-acting insulin for the control of high blood sugar Approval Date: April 2000 2006 Revenue: $2.172 billion Percentage of Sanofi-Aventis’s Total Revenue: 5.61 percent About Lantus Lantus

Proper name: Docetaxel Type: Anticancer Drug Developer: Sanofi-Aventis Location: Paris, France Website: www.sanofi-aventis.com Indication(s): For the treatment of locally advanced or metastatic breast cancer after failure of prior anthracycline chemotherapy; locally advanced or metastatic non-small-cell lung cancer (NSCLC); first-line therapy in combination with cisplatin for unresectable, locally advanced or metastatic NSCLC; hormone-refractory metastatic prostate cancer; in combination

Proper name: Bevacizumab Type: Anticancer Developer: Genentech Inc. Location: South San Francisco, California Web address: www.gene.com Indication(s): For treatment of people diagnosed with metastatic colorectal cancer for the first time, and receiving intravenous 5-fluorouracil (5-FU)-based chemotherapy. In combination with carboplatin and paclitaxel for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small-cell lung cancer. Approval

Proper name: Epoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): For the treatment of anemia in patients with chronic renal failure who are on dialysis Approval Date: June 1989 2006 Revenue: $2.511 billion Percentage of Amgen’s Total Revenue: 17.60 percent Dialysis treatment indication The term “life-saving drug” really applies to Epogen and its class of drugs that address end-stage severe indications

Proper name: Imatinib mesylate Type: Anticancer Drug Developer: Novartis AG Location: Basel, Switzerland Website: www.novartis.com Indication(s): For the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and other malignancies Approval Date: May 2001 2006 Revenue: $2.554 billion Percentage of Novartis’ Total Revenue: 6.90 percent CML and GISTs Chronic myelogenous leukemia (CML), also called chronic granulocytic and chronic myelocytic leukemia, is

Proper name: Pegfilgrastim Type: Anticancer, anti-infective Manufacturer: Amgen Inc. Location: Thousand Oaks, California Web address: www.amgen.com Indication(s): To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia Approval Date: January 2002 2006 Revenue: $2.710 billion Percentage of Amgen’s Total

Proper name: Infliximab Type: Anti-inflammatory Drug Developer: Centocor Inc. Location: Malvern, Pennsylvania Website: www.centocor.com Indication(s): For the treatment of moderately to severely active Crohn’s disease, reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn’s disease; for the treatment of active ankylosing spondylitis; for reducing signs and symptoms of active arthritis in patients with

Proper name: Trastuzumab Type: Anticancer Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): For the treatment of metastatic breast cancer Approval Date: September 1998 Total 2006 Revenue (Reported by Roche): $3.150 billion 2006 Revenue Reported by Genentech: $1.123 billion Percentage of Roche’s Total Revenue: 9.12 percent Percentage of Genentech’s Total Revenue: 13.29 percent Breast cancer statistics and the market Breast

Proper name: Epoetin alpha Type: Antianemic Drug Developer: Ortho Biotech Products LP Location: Bridgewater, New Jersey Website: www.orthobiotech.com Indication(s): Eprex (outside the U.S.): To treat anemia associated with kidney disease by stimulating bone marrow to produce more red blood cells; to treat anemia and reduce the need for a blood transfusion for patients receiving chemotherapy for solid tumors, malignant lymphoma or multiple myeloma; as an alternative to a blood transfusion in

Proper name: Rituximab Type: Anticancer, anti-inflammatory Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): For the treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL), slow-growing NHL, aggressive NHL in combination with the chemotherapy drugs cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), to diffuse large B-cell lymphoma in combination with CHOP or other chemotherapy

Proper name: Darbepoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To treat anemia associated with chronic renal failure and to treat chemotherapy-induced anemia in patients with nonmyeloid malignancies Approval Date: September 2001 2006 Revenue: $4.121 billion Percentage of Amgen’s Total Revenue: 28.88 percent Anemia indication Chronic renal failure, also called kidney failure, is described as “a

Proper name: Etanercept Type: Anti-inflammatory Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To reduce the signs and symptoms of moderate to severe rheumatoid arthritis, moderate to severe polyarticular-course juvenile rheumatoid arthritis (JRA), psoriatic arthritis, ankylosing spondylitis (AS) and moderate to severe plaque psoriasis. Approval Date: November 1998 2006 Revenue: $4.379 billion Percentage of Amgen’s Total Revenue: 20

Drug name (maker) Indication Revenue for 2006 1 Enbrel (Amgen) Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis $4,379M 2 Aranesp (Amgen) Anemia $4,121M 3 Rituxan (Genentech) Non-Hodgkin’s lymphoma, rheumatoid arthritis $3,881M 4 Procrit/Eprex (Ortho Biotech) Anemia $3,180M 5 Herceptin (Genentech) Breast cancer $3,150M 6 Remicade (J&J) Crohn’s disease, ankylosing spondylitis, arthritis, ulcerative colitis, rheumatoid

I Biotechnology Someone could have sold plenty of T-shirts bearing that logo, considering the good fortune the biotechnology industry had in raising money for drug development and in selling its approved drugs last year. In 2006, it seemed as if everyone wanted to join the biotechnology fan club, as the number of R&D deals, financings, product approvals, number of employees, pipeline advancements, revenues and other key factors continued to increase and build upon the industry’s 30-year track

Drug Maker 2005 revenue 1 Lipitor Pfizer $12.187b 2 Plavix Bristol-Myers Squibb Sanofi-Aventis $3.823b $2.435b 3 Seretide/Advair GlaxoSmithKline $5.465b 4 Norvasc Pfizer $4.706b 5 Nexium AstraZeneca $4.633b 6 Zocor Merck $4.4b 7 Zyprexa Eli Lilly $4.202b 8 Diovan group Novartis $3.676b 9 Risperdal Johnson & Johnson $3.552b 10 Effexor Wyeth $3.5b 11 Zoloft Pfizer $3.256b 12 Fosamax franchise Merck $3.2b 13 COZAAR/HYZAAR Merck $3.0b 14

All figures are in U.S. dollars unless otherwise indicated. Abbott Laboratories YE 2005 YE 2004 Revenue $22.338B $19.680B Net income $3.372B $3.236B Earnings per share $2.16/share $2.06/share Average shares outstanding 1.564B 1.571B Market capitalization $69.24B (3/06)* Amgen Inc. YE 2005 YE 2004 Revenue $12.430B $10.550B Net income $3.674B $2.363B Earnings per share $2.97/share $1.86/share Average shares outstanding 1.236B 1.271B Total assets $29.297M

Fisher Scientific International Inc. $5,579M Invitrogen Corp. $1,199M bioMerieux SA $1,193M Applied Biosystems Inc. $1,787M PPD Inc. (Pharmaceutical Product Development Inc.) $1,037M Idexx Laboratories Inc. $638M Diagnostic Products Corp. $481M Qiagen Inc. $398M Affymetrix Inc. $368M Gen-Probe Inc. $306M Bruker Biosciences Corp. $298M Sigma-Aldrich Corp. $258M Takara Bio Inc. $128M SOURCE: BioScan: The Worldwide Biotech Industry Reporting Service

Amgen Inc. $12,430M Genentech Inc. $6,633M Genzyme Corp. $2,735M Serono International SA $2,586M Biogen Idec Inc. $2,423M Gilead Sciences Inc. $2,028M Chiron Corp. $1,921M MedImmune Inc. $1,244M Cephalon Inc. $1,212M Celgene Corp. $537M ImClone Systems Inc. $383M Cambridge Antibody Technology Group plc $338M Serologicals Corp. $275M Aeolus Pharmaceuticals Inc. $252M AEterna Zentaris Inc. $247M QLT Inc. $242M SOURCE: BioScan: The Worldwide Biotech Industry

Drug name (maker) 2005 2004 2003 1 Procrit/Eprex (Ortho Biotech) $3.324B $3.589B $3.984B 2 Aranesp (Amgen) $3.273B $2.5B $1.6B 3 Enbrel (Amgen) $2.573B $1.9B $1.3B 4 Remicade (J&J) $2.535B $2.145B $1.729B 5 Epogen (Amgen) $2.455B $2.6B $2.4B 6 Herceptin (Genentech) $2.416B $1.591B $2.064B 7 Neulasta (Amgen) $2.288B $1.7B $1.3B 8 Gleevec (Novartis) $2.170B $1.634B $1.128B 9 Taxotere (Sanofi-Aventis) $1.956B $1.747B $1.577B 10 Rituxan (Genentech